<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114436">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02065167</url>
  </required_header>
  <id_info>
    <org_study_id>ORTHO -2</org_study_id>
    <secondary_id>2012-002010-39</secondary_id>
    <nct_id>NCT02065167</nct_id>
  </id_info>
  <brief_title>Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip</brief_title>
  <acronym>ORTHO-2</acronym>
  <official_title>Evaluation of Safety and Feasibility of Bone Marrow Derived Autologous MSCs to Enhance Bone Healing in Patients With Avascular Necrosis of the Femoral Head</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autonoma de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Autonoma de Madrid</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to assess the safety and feasibility  of cellular therapy derived from bone
      marrow, to help bone healing in patients with avascular necrosis of the hip.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and feasibility of an in situ single injection of a high dose of
      autologous bone marrow-derived, in vitro expanded Mesenchymal stem cells, and its
      contribution to the resolution of the early stages of avascular osteonecrosis of the femoral
      head.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complication rate</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Includes early local complication rate plus global complication rate, as the percentage of patients with local or general complications at 52 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complication rate</measure>
    <time_frame>6,12,24,104 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Local and general complication rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of disease to the next stage</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of necrotic bone in the femoral head in MRI</measure>
    <time_frame>12 weeks and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>6,12,24,52,104 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum levels of bone turnover markers</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Avascular Necrosis of the Femoral Head</condition>
  <arm_group>
    <arm_group_label>Cultured autologous Mesenchymal Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.
20x106 cells per cc in a single administration of 7cc</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cultured autologous Mesenchymal Cells</intervention_name>
    <description>Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.</description>
    <arm_group_label>Cultured autologous Mesenchymal Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age 18 to 65, both sexes

          -  Early avascular necrosis of the fem oral head (MRI diagnosis): Ficat and Arlet 0, 1,
             or 2 (Steinberg stages 0, I, IIA, IIB, or IIC)

          -  Sym ptom atic osteonecrosis with less than 6 months of evolution

          -  Able to provide informed consent, and signed informed consent

          -  Medical health care coverage

        Exclusion Criteria:

          -  Pregnancy, breast feeding women and women who are of childbearing age and not
             practicing adequate birth control.

          -  Participation in another therapeutic trial in the previous 3 m onths

          -  Stages 3 or m ore (Ficat and Arlet) or III or m ore (Steinberg) of severe fem oral
             head osteonecrosis,primarily based on diagnosis by im aging (X-Rays, MRI).

          -  Flattening or collapse of the fem oral head (Steinberg stage IV) or articular
             cartilage collapse at the time of core decompression surgery.

          -  Septic arthritis.

          -  Stress fracture.

          -  Non-osteonecrosis metabolic bone diseases (particularly Paget's disease of bone,
             osteogenesis imperfecta, primary hyperparathyroidism , fibrous dysplasia monostotic,
             polyostotic McCune-Albright syndrome] and osteopetrosis).

          -  Any active bisphosphonate treatment or any history of intravenous (IV) treatment.

          -  History of prior or concurrent diagnosis of HIV-, Hepatitis-B- or
             Hepatitis-C-infection

          -  Active hepatitis B or hepatitis C infection at the time of screening.

          -  Known allergies to products involved in the production process of MSC.

          -  History of neoplasia or current neoplasia in any organ.

          -  Corticoid or immunosuppressive therapy more than one week in the two months prior to
             study inclusion

          -  Patients who will require continuous, systemic, high dose corticosteroid therapy
             (more than 7.5 m g/day) within 6 months after surgery.

          -  Patients who are in active treatment for cancer or blood dyscrasia, or have received
             chemotherapy, radiotherapy or immunotherapy in the past 2 years.

          -  History of regular alcohol consumption exceeding 2 drinks/day  within 6 months of
             screening and/or history of illicit drug use.

          -  Serum AST (SGO T)/ALT (SGPT) &gt; 2.5 X (institutional standard range).

          -  MRI-incompatible internal devices (pacemakers, aneurysm clips, etc).

          -  Body mass index (BMI) of 40 kg/m ² or greater.

          -  Patients unable to tolerate general anesthesia defined as an American Society of
             Anesthesiologists (ASA) criteria of &gt; 2.

          -  Insulin dependent diabetes

          -  Patients with poorly controlled diabetes mellitus (HbA1C &gt; 8%), or with peripheral
             neuropathy, or known concomitant vascular problems.

          -  Patients receiving treatment with hematopoietic growth factors or anti-vasculogenesis
             or antiangiogenesis treatment.

          -  Traumatic osteonecrosis.

          -  Adult in the care of a guardian (Subject legally protected)

          -  Im possibility to meet at the appointments for the clinical follow up.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Gomez-Barrena, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad Autonoma de Madrid, Hospital la Paz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enrique Gomez-Barrena, Prof</last_name>
    <email>enrique.gomezbarrena@uam.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Orthopaedic Surgery, Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Hernigou, Dr</last_name>
      <email>philippe.hernigou@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Hernigou, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedic Surgery, CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Rosset, Dr</last_name>
      <email>rosset@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Rosset, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michaela Doering, Dr</last_name>
      <email>michaela.doering@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedic Trauma, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>8907581</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florian Gebhard, Prof</last_name>
      <email>florian.gebhard@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Florian Gebhard, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Baldini, Prof</last_name>
      <email>nicola.baldini@ior.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Baldini, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servicio de Cirugía Ortopédica y Traumatología &quot;A&quot;, Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Gomez-Barrena, Prof</last_name>
      <email>enrique.gomezbarrena@uam.es</email>
    </contact>
    <investigator>
      <last_name>Enrique Gomez-Barrena, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.reborne.org</url>
    <description>web page of the REBORNE consortium</description>
  </link>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 14, 2014</lastchanged_date>
  <firstreceived_date>February 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Autonoma de Madrid</investigator_affiliation>
    <investigator_full_name>Prof Enrique Gomez-Barrena</investigator_full_name>
    <investigator_title>Full Professor and Chair of orthopaedic surgery</investigator_title>
  </responsible_party>
  <keyword>avascular necrosis of femoral head</keyword>
  <keyword>cell therapy</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Osteonecrosis</mesh_term>
    <mesh_term>Femur Head Necrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
